FlipBooth - The Pinoy Youtube - Free Pinoy 24 TV Videos And Channel Site

The Pinoy Youtube - Free Pinoy 24 TV Videos And Channel Site

Follow us in Twitter Find us in Facebook  



Be the first to test out our newest site: Awitin - Pinoy Musics @ http://www.awitin.com


 

Anatomia Corpo Umano 3D con il Visible Human Server

Tags : Tech

This content requires JavaScript and Macromedia Flash Player 7 or higher. Get Flash



Video Description for Anatomia Corpo Umano 3D con il Visible Human Server

AB Techno Blog
Il Visible Human Server creato dall'EPFL ( Ecole Polytechnique Fédérale di Losanna ) é un fantastico Simulatore Virtuale Tridimensionale dell'Anatomia del Corpo Umano con cui puoi Visualizzare, Sezionare, Ruotare e Zoomare qualsiasi punto, regione, organo o sistema del corpo umano, permettendoti di studiare e analizzare nel minimo dettaglio l'anatomia e la fisiologia umana, leggi il post completo su AB Techno Blog - Tecnologie, Strumenti e Servizi per un KnowHow creativo


AB Techno Blog
Il Visible Human Server creato dall'EPFL ( Ecole Polytechnique Fédérale di Losanna ) é un fantastico Simulatore Virtuale Tridimensionale dell'Anatomia del Corpo Umano con cui puoi Visualizzare, Sezionare, Ruotare e Zoomare qualsiasi punto, regione, organo o sistema del corpo umano, permettendoti di studiare e analizzare nel minimo dettaglio l'anatomia e la fisiologia umana, leggi il post completo su AB Techno Blog - Tecnologie, Strumenti e Servizi per un KnowHow creativo


Brought to you by http://www.flipbooth.com - FlipBooth - Free Pinoy 24 TV


Comments
Eniuzzo

come posso scaricarlo? ti prego, mi servirebbe grazie in
Shenia Montes

eniuzzo devi scaricare e installare atube catcher
10UnderScore10

Chopin notturno op 27 no 2
Agostino Prezioso

incredibile sensazionale ben venuta tecnologia grazie


Having problems with the video?
  • If there are multiple servers, you can choose between different servers. Click on Server 1, Server 2, etc...
  • We recommend that you have a high-speed Internet connection because of the High Definition and length of the videos. Pause the player for a while to let it buffer if your Internet speed is slow, and then play it again. 5 minutes is recommended.
  • In some videos, you may need to click the NEXT button to proceed watching.


F.A.Q.
  • There is an ad blocking the video. What do I do?
    We need these advertisements to fund the site so that you can watch videos for free. Refresh the page (may be multiple times) to make them disappear.

  • What is that music in the background?
    The background music you here may come from advertisements. Try refreshing the page to disable them or find the icon in the bottom left corner of the advertisement and click it to close it.

  • It always say "buffering" and keeps stopping.
    Your Internet connection may be slow. Try pausing the video for a while before resuming. It is recommended to pause the movie for about 5 minutes. In extreme cases, try pausing up to 30 minutes.

  • Video not found or 404 error?
    The server the movie is hosted may be down or have been deleted. In this case, try choosing a different server.

  • What should my Internet speed need to be?
    The recommended (not required) speed is 3Mbps/3000Kbps and above. To check your speed, go to http://www.speakeasy.net/speedtest/

  • What else do I need?
    You may also need to have either or both of these plugins installed: Adobe Flash Player and Microsoft Silverlight.



News Report:


Gates-backed tuberculosis drug to enter late-stage testing

CHICAGO, USA - The first experimental drug that fights both conventional and drug-resistant forms of tuberculosis is advancing to late-stage clinical testing, researchers said on Wednesday, raising hope for a new way to stem the growing threat of drug-resistant TB.
 
The trial, financed in part by the Bill & Melinda Gates Foundation, will test the safety and effectiveness of a new three-drug cocktail known as PaMZ that in mid-stage testing helped to significantly reduce treatment times.
 
In a statement announcing the trial, Microsoft co-founder Bill Gates, co-chair of the Gates Foundation, said the treatment could "reduce the time required to cure drug-resistant TB from two years to just six months" and sharply cut the cost of a cure in low-income countries. He called on other funding groups to back the trial, which is estimated to cost $58 million.
 
The World Health Organization estimates that 8.6 million people developed TB in 2012 and 1.3 million died from the disease. According to the WHO, half a million people became sick with dangerous superbug strains of tuberculosis in 2012, and as many as 2 million people worldwide may be infected with drug-resistant TB by 2015.
 
The trial, set to begin in November, will span some 50 study sites across Africa, Asia, Eastern Europe and Latin America.
 
If successful, the oral treatment would eliminate the need for injectable drugs and reduce the cost of multiple-drug-resistant TB therapy in some countries by more than 90 percent in those patients whose TB is sensitive to the three drugs.
 
The therapy also promises to be compatible with commonly used treatments for human immunodeficiency virus or HIV, helping the millions of people infected with both TB and HIV, the virus that causes AIDS.
 
Jan Gheuens, who manages the TB drug program for the Gates Foundation, said the study's results could be ready by 2017, and if the findings are positive, approval could be expected by the end of 2018.
 
Dr. Mel Spigelman, chief executive officer of the TB Alliance, a non-profit research group that will conduct the study, said the treatment will only be effective in about a third of patients with multiple-drug resistant TB or MDR-TB.
 
But even at that rate, he said the therapy could help "revolutionize" treatment because currently, only about 15 percent of patients with MDR-TB get treatment, and only half of those are cured.
 
Standard treatment for TB usually includes a mix of four drugs over a period of six months. MDR-TB can take 18 to 24 months to treat.
 
The trial announcement followed the successful approval of Johnson & Johnson's drug, bedaquiline, in 2012 for the treatment of drug-resistant TB. This was the first new TB drug in more than 40 years. Last fall, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting conditional marketing approval for delamanid, a treatment for drug-resistant TB being developed by Japan's Otsuka. — Reuters





Buy Ads Directly on this website


Subscribe To
Url
Twitt This Add To Facebook Add To Blinklist Add To Technorati Add To Del.icio.us Digg This Video Add To Reddit Stubmle This Video



Related Videos